Is Innate Pharma SA (IPHA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 20.7% / 30% | 53.9% / 30% | 1.1% / 30% | 19.31% / 5% | ✗ NOT HALAL |
| DJIM | 20.7% / 33% | 53.9% / 33% | 1.1% / 33% | 19.31% / 5% | ✗ NOT HALAL |
| MSCI | 27.9% / 33% | 72.7% / 33% | 1.5% / 33% | 19.31% / 5% | ✗ NOT HALAL |
| S&P | 20.7% / 33% | 53.9% / 33% | 1.1% / 33% | 19.31% / 5% | ✗ NOT HALAL |
| FTSE | 27.9% / 33% | 72.7% / 33% | 1.5% / 50% | 19.31% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -689.6% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -38.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$7M |
| Free Cash Flow | -$7M |
| Total Debt | $31M |
| Current Ratio | 1.3 |
| Total Assets | $111M |
Price & Trading
| Last Close | $1.25 |
| 50-Day MA | $1.62 |
| 200-Day MA | $1.87 |
| Avg Volume | 20K |
|
52-Week Range
$1.17
| |
About Innate Pharma SA (IPHA)
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Innate Pharma SA (IPHA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Innate Pharma SA is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Innate Pharma SA's debt ratio?
Innate Pharma SA's debt ratio is 20.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 27.9%.
What are Innate Pharma SA's key financial metrics?
Innate Pharma SA has a market capitalization of $126M, and revenue of $13M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.